Severe immune thrombocytopenia following COVID-19 vaccination (Moderna) and immune checkpoint inhibitor

• Published in: The American journal of emergency medicine Vol. 56; pp. 395.e1 - 395.e3
• Main Authors: Chong, Kah-Meng, Yang, Ching-Yao, Lin, Chien-Chin, Lien, Wan-Ching
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2022; Elsevier Limited
• Subjects: Adenocarcinoma; Asian people; Blood platelets; Cancer vaccines; Coronaviruses; COVID-19; COVID-19 vaccines; COVID-19 Vaccines - adverse effects; Emergency; Emergency medical care; Female; Hemoptysis; Hepatitis; Humans; Idiopathic thrombocytopenic purpura; Immune Checkpoint Inhibitors; Immune thrombocytopenia; Immunotherapy; Inoculation; Lung cancer; Moderna vaccine; Monoclonal antibodies; mRNA; mRNA-based vaccine; Pandemics; Patients; Prednisolone; Purpura, Thrombocytopenic, Idiopathic - chemically induced; Purpura, Thrombocytopenic, Idiopathic - drug therapy; Side effects; Targeted cancer therapy; Thrombocytopenia; Thrombocytopenia - chemically induced; Vaccination - adverse effects; Vaccines; United States > US; COVID-19; Moderna vaccine; Immune checkpoint inhibitors; mRNA-based vaccine; Immune thrombocytopenia

Safe and effective prophylactic vaccines are urgently needed to contain the coronavirus disease 2019 (COVID-19) pandemic. However, several vaccination-related adverse effects have been reported. Here, we report a rare case of severe immune thrombocytopenia occurring 3 days after receiving the mRNA-1...